Since the introduction of highly active antiretroviral therapy more than 2 decades ago, HIV-related deaths have dramatically decreased and HIV infection has become a chronic disease. Due to the inability of antiretroviral drugs to eradicate the virus, treatment of HIV infection requires a systemic lifelong therapy. However, even when successfully treated, HIV patients still show increased incidence of age-associated co-morbidities compared with uninfected individuals. Virus- induced immunosenescence, a process characterized by a progressive decline of immune system function, contributes to the premature ageing observed in HIV patients. Although antiretroviral therapy has significantly improved both the quality and length of patient lives, the life expectancy of treated patients is still shorter compared with that of uninfected individuals. In particular, while antiretroviral therapy can contrast some features of HIV-associated immunosenescence, several anti-HIV agents may themselves contribute to other aspects of immune ageing. Moreover, older HIV patients tend to have a worse immunological response to the antiviral therapy. In this review we will examine the available evidence on the role of antiretroviral therapy in the control of the main features regulating immunosenescence.

Franzese, O., Barbaccia, M.L., Bonmassar, E., & GRAZIANI, G. (2018). Beneficial and Detrimental Effects of Antiretroviral Therapy on HIV-Associated Immunosenescence. CHEMOTHERAPY, 63(2), 64-75 [10.1159/000487534].

Beneficial and Detrimental Effects of Antiretroviral Therapy on HIV-Associated Immunosenescence

Franzese, Ornella
;
Barbaccia, Maria Luisa;Bonmassar, Enzo;Graziani, Grazia
2018-03-13

Abstract

Since the introduction of highly active antiretroviral therapy more than 2 decades ago, HIV-related deaths have dramatically decreased and HIV infection has become a chronic disease. Due to the inability of antiretroviral drugs to eradicate the virus, treatment of HIV infection requires a systemic lifelong therapy. However, even when successfully treated, HIV patients still show increased incidence of age-associated co-morbidities compared with uninfected individuals. Virus- induced immunosenescence, a process characterized by a progressive decline of immune system function, contributes to the premature ageing observed in HIV patients. Although antiretroviral therapy has significantly improved both the quality and length of patient lives, the life expectancy of treated patients is still shorter compared with that of uninfected individuals. In particular, while antiretroviral therapy can contrast some features of HIV-associated immunosenescence, several anti-HIV agents may themselves contribute to other aspects of immune ageing. Moreover, older HIV patients tend to have a worse immunological response to the antiviral therapy. In this review we will examine the available evidence on the role of antiretroviral therapy in the control of the main features regulating immunosenescence.
Online ahead of print
Rilevanza internazionale
Articolo
Esperti anonimi
Settore BIO/14
English
Antiretroviral therapy; CD28; HIV; Immunosenescence; Inflammation; T cells; Telomerase
Franzese, O., Barbaccia, M.L., Bonmassar, E., & GRAZIANI, G. (2018). Beneficial and Detrimental Effects of Antiretroviral Therapy on HIV-Associated Immunosenescence. CHEMOTHERAPY, 63(2), 64-75 [10.1159/000487534].
Franzese, O; Barbaccia, Ml; Bonmassar, E; Graziani, G
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Chemotherapy 2018.pdf

non disponibili

Licenza: Copyright dell'editore
Dimensione 2.52 MB
Formato Adobe PDF
2.52 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/195625
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 8
social impact